N@N

GILEAD SCIENCES, INC. (NASDAQ:GILD), Down By 7.96% ($3.60) From $45.200 After BUYINS.NET Report Predicted Stock Would Go Down D

^{Published on 2013-03-26 07:46:51 - WOPRAI}
 

March 26, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, March 25th 2013 stating that GILEAD SCIENCES, INC. (NASDAQ:GILD) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=gild&id=356631

At the time this story was written, GILEAD SCIENCES, INC. (NASDAQ:GILD) is Down By $3.60 (7.96%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

GILEAD SCIENCES, INC. (NASDAQ:GILD) - Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; Viread and Hepsera oral formulations for the treatment of chronic hepatitis B; Letairis, an oral formulation for pulmonary arterial hypertension; Ranexa, a tablet for chronic angina; Lexiscan/Rapiscan, a test that detects and characterizes coronary artery disease; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, a capsule for the treatment and prevention of influenza A and B. The company also provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. In addition, it has product candidates in various stages for the treatment of HIV, which include integrase single-tablet regimen Quad; Cobicistat and Elvitegravir in Phase III; and GS-7340 in Phase II, as well as for liver disease, which consist of GS-7977 in Phase III; GS-5885, GS-9451, and GS-6624 in Phase II; and GS-7340, GS-9620, and GS-9669 in Phase I. Further, the company s product candidates in various stages for the treatment of cardiovascular/metabolic diseases comprise Ranolazine in Phase III; and for the treatment of respiratory diseases consist of Aztreonam for inhalation solution in Phase III, as well as GS-6624 in Phase I. Additionally, it has product candidates in various stages for inflammation/oncology diseases that include GS-1101 in Phase III; GS-1101 and GS-6624 in Phase II; and GS-9973 in Phase I. The company was founded in 1987 and is headquartered in Foster City, California..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net